Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
about
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta roleNew blood markers detection technology: A leap in the diagnosis of gastric cancerCirculating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerCurrent Status of CTCs as Liquid Biopsy in Lung Cancer and Future DirectionsNon-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancerMolecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancersBiosensors for the detection of circulating tumour cells.Dynamic changes in numbers and properties of circulating tumor cells and their potential applicationsClinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch SystemLiquid biopsies: genotyping circulating tumor DNAMicrofluidic enrichment for the single cell analysis of circulating tumor cells.Liquid biopsy in early stage lung cancerBlood-based Tumor Markers in Lung CancerLiquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoringCirculating tumor cells versus circulating tumor DNA in lung cancer-which one will win?Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancerEMT, CTCs and CSCs in tumor relapse and drug-resistanceBlood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-AnalysisDetection of circulating tumor DNA in early- and late-stage human malignanciesNon-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNAEnrichment and single-cell analysis of circulating tumor cells.Characteristics of circulating tumor cells in organ metastases, prognosis, and T lymphocyte mediated immune response.Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer.Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lungDetection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNAPrognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patientsAnalyzing epidermal growth factor receptor mutation status changes in advanced non-small-cell lung cancer at different sampling time-points of blood within one day.Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutationsKRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer.What are we learning from the cancer genome?Liquid biopsy: monitoring cancer-genetics in the blood.Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq.Novel molecular tumor cell markers in regional lymph nodes and blood samples from patients undergoing surgery for non-small cell lung cancer.An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer.Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: a meta-analysisQuantification of rare circulating tumor cells in non-small cell lung cancer by ligand-targeted PCR.Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model.The stimulatory activity of plasma in patients with advanced non-small cell lung cancer requires TLR-stimulating nucleic acid immunoglobulin complexes and discriminates responsiveness to chemotherapy.
P2860
Q26769734-C7012C65-A8AC-4346-B735-64020C8A3D91Q26774503-DA3B9947-6D45-47CA-92A1-B0B816513B76Q26775376-47CC395A-BC7A-4DB9-84FE-B1982D520A5CQ26781333-46350B11-2260-4622-A9BD-CB612700BCABQ26801357-4F2A28AF-C2AD-4CF7-B5B3-AA6E6259D4C0Q26822406-9E5F6634-AA62-4973-B0D7-4DE529A01E66Q26827228-D58D3A69-9C71-4B23-AC74-BF25F53CF482Q26853569-73D55CB0-F5A1-4EEC-90E6-7898B57D5876Q27004790-3B17426D-F990-4C15-B912-4C3A9F87650BQ27010159-F03955A4-503E-4636-9695-8C6EC39B7866Q27340255-2F7D1A8C-99CD-4249-A4AE-0F32AE1269DBQ28065994-0B28E285-41DD-44EA-B11A-0D7E7C7659A0Q28072736-6F976AEB-0681-49BF-AB8D-5F28C10F3029Q28076191-D5D2D868-5022-46E6-8261-0F2E9B1D026CQ28077340-6AABFA36-8769-4A9D-9520-A964331F7BC2Q28082499-569D681C-BEE9-47DD-9F12-5AD13EA10BCBQ28082935-DA9F8AF5-B683-4CD2-80D8-B187CB658745Q28087366-CFEE4C71-CA2C-4FD0-862F-58B005E72E9AQ29615778-6F0024BF-CC8C-47CD-BFD3-B0F68E5906DCQ29620083-1C4FF6B6-D26C-4CA2-B6C9-BC076C6D8B53Q30357985-00532E72-6B04-4C13-BCF6-5507C620C0EBQ33650301-DED217F6-C0B1-40E0-A88B-5FC3DFEF52C8Q33679694-002E6FF4-31F9-4207-A650-103E58C60A2FQ33727597-5B4D5283-303F-4C8C-8F32-D108E3B869E4Q33737740-27FC849F-1B01-47F4-997F-F995FEE52B27Q33779727-AACF4F4E-2ACF-4E6C-BE19-306AB6191D42Q33798634-5EF8ECB8-C671-4918-92E6-C18C2D38EFD3Q33863388-982D0D68-F1CC-4C52-9A1A-687E7937B7C6Q33908889-AC8810C2-8361-425C-B952-2FF39E78204DQ34066371-B245C9C7-1B0D-4D68-B7EA-80034853FD9EQ34213994-1E642935-7838-442E-B504-5BD7D5109C48Q34356149-1F716DE5-130B-4829-9C8A-6933BD138535Q34467274-586B4428-6A2E-4403-AA35-286AC5A1B6EEQ34720505-D0850E66-3664-4DB5-874B-04CB842425D8Q34826007-B83B24B3-10D2-49BD-A62A-3CC14C83B51BQ35034044-5C635173-D3B5-405D-B328-D59E0A4F846AQ35040775-76B8702B-DF37-4087-8CF9-724518353B7BQ35063733-67CF76C6-3813-4769-9976-B3842056AA61Q35068046-24785818-D993-487B-9A32-A63B2FA5CA4DQ35189391-13C7FC68-B99F-44A7-848D-E1FF9527ED9A
P2860
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Evaluation of circulating tumo ...... l of pertuzumab and erlotinib.
@en
Evaluation of circulating tumo ...... l of pertuzumab and erlotinib.
@nl
type
label
Evaluation of circulating tumo ...... l of pertuzumab and erlotinib.
@en
Evaluation of circulating tumo ...... l of pertuzumab and erlotinib.
@nl
prefLabel
Evaluation of circulating tumo ...... l of pertuzumab and erlotinib.
@en
Evaluation of circulating tumo ...... l of pertuzumab and erlotinib.
@nl
P2093
P50
P1476
Evaluation of circulating tumo ...... l of pertuzumab and erlotinib.
@en
P2093
Andrea Pirzkall
Brett G M Hughes
Elizabeth A Punnoose
Garret M Hampton
Lukas C Amler
Rajiv Raja
Siminder Atwal
Weiqun Liu
P304
P356
10.1158/1078-0432.CCR-11-3148
P407
P577
2012-04-05T00:00:00Z